Thyroid Eye Disease Treatment Market Analysis & Forecast: 2025-2032

Thyroid Eye Disease Treatment Market Size and Forecast – 2025 – 2032

The Global Thyroid Eye Disease Treatment Market size is estimated to be valued at USD 1.2 billion in 2025 and is expected to reach USD 2.05 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 8.1% from 2025 to 2032.

Global Thyroid Eye Disease Treatment Market Overview

Thyroid eye disease treatment products address inflammation, tissue expansion, and visual impairment associated with autoimmune thyroid disorders. These include corticosteroids, immunomodulatory drugs, biologic therapies, radiation therapy solutions, and surgical interventions such as orbital decompression tools. Recently developed biologics specifically target disease pathways to reduce proptosis and inflammation. Product differentiation centers on efficacy in reducing symptoms, safety profile, treatment duration, and improvement in patient quality of life.

Key Takeaways

• Market segments show clear dominance: The biologics and monoclonal antibodies segment holds a commanding 45% market share, indicating a shift toward sophisticated immunotherapies as the leading treatment modality.

• The hospital setting remains the largest end user, corroborating the preference for specialized, inpatient management of complicated TED cases.

• From a regional perspective, North America maintains its leadership due to significant healthcare spending and robust R&D pipelines, accounting for approximately 40% of the global share in 2025.

• Meanwhile, the Asia Pacific region emerges as the fastest-growing region with a CAGR exceeding 10% because of rising disease incidence and improved healthcare accessibility.

Thyroid Eye Disease Treatment Market Segmentation Analysis

To learn more about this report, Download Free Sample

Thyroid Eye Disease Treatment Market Insights, By Treatment Type

Biologics and Monoclonal Antibodies dominate the market share with 45%. Biologics and monoclonal antibodies have become the cornerstone of treatment due to their targeted mechanism of action and improved safety profile, significantly reducing disease progression rates. This segment is the fastest growing, supported by rising approvals and expanded indications. Corticosteroids remain integral for symptomatic management but face challenges due to side effects and relapse risk. Surgical interventions cater primarily to severe, refractory cases, while radiation therapy is limited due to emerging safer alternatives.

Thyroid Eye Disease Treatment Market Insights, By Therapeutic Approach

Immunomodulatory Therapy is the dominant segment, accounting for over 50% market share, driven by advanced biologic therapies modulating immune response directly related to TED pathology. It is also the fastest growing subsegment due to ongoing research yielding novel agents. Symptomatic Management continues as a support pillar for managing manifestations such as eyelid retraction and inflammation, but lacks curative potential. Surgical Procedures, while crucial for optic neuropathy or severe proptosis, have limited frequency due to invasiveness. Radiotherapy is less preferred but remains relevant in specific clinical scenarios. Supplementary treatments like lubricants and antioxidants serve as adjuncts rather than isolated therapies.

Thyroid Eye Disease Treatment Market Insights, By End-User

Hospitals dominate with the largest market share of close to 60%, primarily due to their capacity for complex diagnostics, multidimensional treatment delivery, and postoperative care. Hospitals are also central to clinical trials, influencing the market’s research-driven expansion. Specialty Clinics represent the fastest-growing subsegment, benefitting from increasing patient preference for specialized, outpatient management and personalized care pathways. Ambulatory Surgical Centers function mainly for surgical interventions but remain a smaller share. Research Institutes contribute indirectly to market dynamics through clinical studies and the development of treatment protocols.

Thyroid Eye Disease Treatment Market Trends

• In recent years, the Thyroid Eye Disease Treatment market trend has notably shifted toward advanced biologics, exemplified by the FDA approval and widespread adoption of teprotumumab, which has revolutionized treatment outcomes.

• Digital health tools and teleophthalmology platforms have also gained traction, especially post-pandemic, facilitating better disease monitoring and compliance.

• Real-world data from 2024 indicates an 18% year-over-year growth in telemedicine consultations related to TED management, highlighting the integration of technology in treatment paradigms.

• Regionally, North America dominates with a significant market share of approximately 40%, attributed to a well-established healthcare infrastructure, high healthcare expenditure, and research investment.

• Asia Pacific exhibits the fastest growth trajectory, showcasing a CAGR of over 10%, fueled by rising disease awareness, expanding hospital infrastructure, and increasing adoption of newer treatment modalities.

• Key players such as Horizon Therapeutics and Novartis are strategically expanding their reach in Asia Pacific through partnerships and payload introduction, influencing regional market dynamics.

Thyroid Eye Disease Treatment Market Insights, By Geography

To learn more about this report, Download Free Sample

North America Thyroid Eye Disease Treatment Market Analysis and Trends

In North America, the dominance in the Thyroid Eye Disease Treatment market is driven by advanced medical facilities, high prevalence rates, and favorable reimbursement policies. The U.S., in particular, holds the bulk of this market share, aided by a mature pharmaceutical ecosystem focused on biologics, leading to consistent growth. Companies like Horizon Therapeutics have capitalized on this by launching teprotumumab, ensuring strong market capture.

Asia Pacific Thyroid Eye Disease Treatment Market Analysis and Trends

Meanwhile, Asia Pacific exhibits the fastest growth, supported by rising healthcare investments, increasing patient pool, and government initiatives to improve specialty treatment access. Countries like India and China are witnessing higher diagnosis rates of TED due to heightened awareness campaigns.

Thyroid Eye Disease Treatment Market Outlook for Key Countries

USA Thyroid Eye Disease Treatment Market Analysis and Trends

The USA remains the largest contributor to market revenue owing to the presence of cutting-edge therapeutic options and a highly developed healthcare infrastructure. Approximately 40% of the global thyroid eye disease treatment revenue is generated from the U.S., where Horizon Therapeutics’ teprotumumab has seen over 50% year-over-year prescription growth in 2024. Strong insurance reimbursements and clinical trial activities further underpin market expansion. The U.S. also benefits from growing endocrinology and ophthalmology specialty clinics dedicated to TED, enhancing patient accessibility to innovative treatments.

India Thyroid Eye Disease Treatment Market Analysis and Trends

India’s market is rapidly evolving, propelled by increasing disease awareness and healthcare spending. Growing public and private hospital infrastructure specializing in autoimmune disorders is catalyzing treatment accessibility. The government’s focus on improving healthcare quality and affordability, along with rising medical tourism for ophthalmic treatments, is transforming the competitive landscape. Novartis and other market players have intensified their presence by launching patient assistance programs and expanding drug distribution networks, aiding the acceleration of market revenue in the region.

Analyst Opinion

• Robust demand-side indicators reveal an increasing adoption rate of biologics and monoclonal antibody therapies among endocrinologists and ophthalmologists. For instance, global prescriptions of teprotumumab, approved recently, surged by over 35% in 2024, underlining the market’s pivot toward targeted therapies.

• On the supply side, manufacturing capabilities for novel immunomodulatory agents have expanded by approximately 22% between 2023 and 2025, driven by increased investment from pharmaceutical companies in active production lines, ensuring steady supply chain resilience.

• Market growth is also propelled by emerging treatment protocols incorporating combination therapies, incorporating corticosteroids with emerging biologics. Clinical trial registrations for these protocols increased by 18% globally in 2024, highlighting the shift in therapeutic regimens.

• Geographic market dynamics illustrate that North America continues to dominate market share due to high healthcare expenditure and established reimbursement frameworks, registering a 40% market share in 2025, while Asia Pacific markets demonstrate rapid growth attributed to expanding patient awareness and improving healthcare infrastructure.

Market Scope

Thyroid Eye Disease Treatment Market Growth Factors

The growing prevalence of autoimmune thyroid conditions, with an estimated 12 million Americans affected by Graves’ disease alone as of 2024, is a critical growth driver. Increasing patient awareness regarding TED and related complications is pushing demand for early diagnostic and therapeutic interventions. Advances in biologics and targeted molecular therapies are transforming the treatment landscape, improving efficacy and reducing relapse rates. Additionally, improved healthcare reimbursement policies in developed countries are facilitating wider accessibility and affordability of costly novel treatments. The rise in specialized ophthalmic care facilities, particularly in regions like North America and Europe, complements market growth dynamics.

Thyroid Eye Disease Treatment Market Development

• In 2024, Viridian Therapeutics announced the submission of a Biologics License Application (BLA) for Veligrotug for the treatment of Thyroid Eye Disease (TED). The submission marked a key regulatory milestone for the company’s lead antibody candidate, supporting its strategy to address significant unmet needs in TED with differentiated efficacy and dosing potential.

• In 2024, DRI Healthcare Trust announced the acquisition of a synthetic royalty interest in U.S. sales of Veligrotug and VRDN-003 for the treatment of Thyroid Eye Disease. The transaction strengthened DRI Healthcare’s royalty portfolio while providing long-term exposure to the commercial success of Viridian’s TED therapies in the U.S. market.

Key Players

Leading Companies of the Market

• Santen Pharmaceutical Co., Ltd.

• Sanofi S.A.

• AbbVie Inc.

• Regeneron Pharmaceuticals, Inc.

• Alexion Pharmaceuticals, Inc.

• Eisai Co., Ltd.

• Amgen Inc.

• Mylan N.V.

• Ipsen S.A.

• Ipsen Bioscience, Inc.

Market leaders are increasingly investing in expanding their biologics portfolio. Horizon Therapeutics’ aggressive market penetration strategy, supported by successful commercialization of teprotumumab, augmented its revenue by 30% in 2024. Meanwhile, Novartis enhanced its competitive positioning through strategic collaborations and licensing agreements in 2023, accelerating access to innovative therapies in emerging markets.

Thyroid Eye Disease Treatment Market Future Outlook

The TED treatment market is expected to grow as awareness increases and early diagnosis becomes more common. Continued innovation in biologic therapies and immune-modulating drugs will enhance treatment efficacy. Expanding access to specialized care and integration of multidisciplinary treatment approaches will further support market growth. Emerging markets are expected to see increased adoption as healthcare infrastructure improves.

Thyroid Eye Disease Treatment Market Historical Analysis

Historically, treatment for thyroid eye disease focused on symptom management through corticosteroids and surgical interventions. Limited disease-specific therapies restricted long-term outcomes. Over time, improved understanding of the autoimmune mechanisms underlying TED led to the development of targeted biologic therapies. These advances transformed the treatment landscape and significantly improved disease management.

Sources

• Primary Research Interviews:

• • Endocrinologists

  • Ophthalmologists

  • Immunologists

  • Hospital Specialists

  • Biopharma Researchers

• Databases:

• • FDA Biologics Data

  • WHO Health Statistics

  • NIH Databases

• Magazines:

• • Ophthalmology Times

  • Endocrine Today

  • BioPharma Dive

  • MedTech Insight

  • PharmaVOICE

• Journals:

• • Ophthalmology Journal

  • Journal of Endocrinology

  • Thyroid Journal

  • Clinical Immunology

  • The Lancet Diabetes & Endocrinology

• Associations:

• • American Thyroid Association

  • Endocrine Society

  • American Academy of Ophthalmology

  • WHO

  • Rare Disease International